Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform
June 26 2023 - 7:30AM
Syneos Health® (Nasdaq:SYNH), a leading fully integrated
biopharmaceutical solutions organization, today announced a
strategic partnership with uMotif, a clinical trial technology
company putting the patient at the center of research. The
collaboration will help accelerate clinical trials and bring new
therapies to patients faster through a more efficient, end-to-end
digital platform that includes robust Electronic Clinical Outcome
Assessment (eCOA) and Electronic Patient-reported Outcomes (ePRO)
capabilities.
In addition to uMotif providing eCOA and ePRO services for
Syneos Health customers, the companies will develop and deploy an
exclusive patient-centric platform to deliver seamless, integrated
customer solutions – including patient identification, recruitment,
eConsent, eDiary, patient engagement and retention, and payments.
Complemented by the Company’s StudyKIK recruitment technology
platform, Syneos Health will build a single application to help
drive better engagement, compliance and retention with patients,
and reduce site burden.
“At Syneos Health, we are constantly evolving our solutions to
address unmet customer, site and patient needs. The partnership
with uMotif is a natural fit as both companies share a forward
thinking approach to technology and are committed to the site and
patient experience,” said Michael Brooks, Chief Operating Officer,
Syneos Health. “We’re excited to collaborate with uMotif to deliver
an integrated, best-in-class, patient-facing solution to bring
clinical trials closer to the patient.”
The uMotif cloud-native and highly configurable platform is
collaboratively designed with patients, healthcare professionals,
monitors, data managers and sponsors. The modern platform can be
quickly adapted to meet protocol specific requirements, providing
optimal flexibility for sponsors, sites and patients.
“We’re excited to work with Syneos Health. We believe our
modern, patient-centric solution is aligned with Syneos Health’s
vision of creating a better patient experience and providing
sponsors with better trials. We also look forward to building a
solution that leverages the power of StudyKIK’s patient
identification, recruitment and retention technology platform and
complements Syneos Health’s focus on patient centric solutions,”
said Steve Rosenberg, CEO, uMotif. “Together, we are deploying a
solution where patient workflow is made simple, easy and effective
– ensuring that participants are fully able and engaged to capture
large volumes of data – to help maximize the success of a clinical
trial.”
This partnership demonstrates Syneos Health’s continued
investment in technology and data solutions that accelerate
clinical development, integrating the voice of the site and patient
to optimize performance for biopharma customers.
About uMotifPutting patients first is in
uMotif’s DNA. The uMotif eCOA/ePRO platform delivers faster,
quality clinical trials and real-world studies by putting patients
at the core of research. Through cloud-hosting in the US, Europe
and China, the GCP, 21 CFR Part 11 and GDPR-compliant platform
supports any study or trial, from Clinical Phase I, II and III
studies through to decentralized or virtual real-world studies.
Find out how uMotif can improve your clinical research programs and
real-world studies at www.umotif.com
About Syneos Health Syneos
Health® (Nasdaq:SYNH) is a leading fully integrated
biopharmaceutical solutions organization built to accelerate
customer success. We translate unique clinical, medical affairs and
commercial insights into outcomes to address modern market
realities.
We bring together a talented team of professionals, who work
across more than 110 countries, with a deep understanding of
patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and
apply advanced business practices to speed our customers’ delivery
of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive
culture that cares for colleagues, customers, patients, communities
and the environment.
To learn more about how we are Shortening the distance from lab
to life®, visit syneoshealth.com.
Investor Relations ContactRonnie SpeightSenior
Vice President, Investor Relations+1 919 745
2745Investor.Relations@syneoshealth.com
Media ContactGary GatyasExecutive Director,
External Communications+1 908 763
3428gary.gatyas@syneoshealth.com
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Oct 2023 to Oct 2024